Top

BY Linda Gilchriest

Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers have found.

A team led by author Emma Holliday, M.D., assistant professor of Radiation Oncology, published its research this month in JAMA Oncology, reporting that of 598 Phase III cancer studies published between 2003 and 2018, only 107, or 17.9 percent, had female corresponding authors.<...

A study by MD Anderson researchers of 598 phase III clinical trials showed only 17.9% of lead investigators were women.

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Clayton Boldt, Ph.D.

According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET inhibitors for treating a difficult-to-treat form of lymphoma.

Research findings were published online in Science Translational Medicine.

The study, led by Michael Green, Ph.D., assistant professor of Lymphoma & Myeloma, showed that transcription factor 4 (TCF4) is the most frequent...

Michael Green, Ph.D.

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Scott Merville

Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...

BY Clayton R. Boldt, Ph.D.

An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...

BY Scott Merville

A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...